BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, Jaehde U, Steeghs N, Huitema ADR, Kloft C. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol 2021;77:441-64. [PMID: 33165648 DOI: 10.1007/s00228-020-03014-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Isberner N, Gesierich A, Balakirouchenane D, Schilling B, Aghai-trommeschlaeger F, Zimmermann S, Kurlbaum M, Puszkiel A, Blanchet B, Klinker H, Scherf-clavel O. Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma. Cancers 2022;14:4566. [DOI: 10.3390/cancers14194566] [Reference Citation Analysis]
2 Opitz P, Zimmermann S, Mc Laughlin AM, Müller L, Fuxius S, Illerhaus G, Scherf-Clavel O, Kloft C, Hempel G; ON-TARGET study consortium. Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS. J Pharm Biomed Anal 2022;221:115033. [PMID: 36148722 DOI: 10.1016/j.jpba.2022.115033] [Reference Citation Analysis]
3 Rodier T, Puszkiel A, Cardoso E, Balakirouchenane D, Narjoz C, Arrondeau J, Fallet V, Khoudour N, Guidi M, Vidal M, Declèves X, Csajka C, Alexandre J, Cadranel J, Fabre E, Wislez M, Goldwasser F, Blanchet B. Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer. Pharmaceutics 2022;14:1844. [DOI: 10.3390/pharmaceutics14091844] [Reference Citation Analysis]
4 Roncato R, Gerratana L, Palmero L, Gagno S, Poetto AS, Peruzzi E, Zanchetta M, Posocco B, De Mattia E, Canil G, Alberti M, Orleni M, Toffoli G, Puglisi F, Cecchin E. An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer. Front Pharmacol 2022;13:897951. [DOI: 10.3389/fphar.2022.897951] [Reference Citation Analysis]
5 Tiako Meyo M, Chen J, Goldwasser F, Hirsch L, Huillard O. A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma. Ther Clin Risk Manag 2022;18:683-98. [PMID: 35837579 DOI: 10.2147/TCRM.S263832] [Reference Citation Analysis]
6 Li Y, Meng L, Ma Y, Li Y, Xing X, Guo C, Dong Z. Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS. Molecules 2022;27:4474. [DOI: 10.3390/molecules27144474] [Reference Citation Analysis]
7 Guchelaar NAD, van Eerden RAG, Groenland SL, Doorn LV, Desar IME, Eskens FALM, Steeghs N, van Erp NP, Huitema ADR, Mathijssen RHJ, Koolen SLW; Dutch Pharmacology Oncology Group. Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer. Biomed Pharmacother 2022;153:113393. [PMID: 35834987 DOI: 10.1016/j.biopha.2022.113393] [Reference Citation Analysis]
8 Noda S, Morita SY, Terada T. Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring. Biol Pharm Bull 2022;45:814-23. [PMID: 35786588 DOI: 10.1248/bpb.b21-01098] [Reference Citation Analysis]
9 Danielak D, Krejčí T, Beránek J. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. European Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ejps.2022.106254] [Reference Citation Analysis]
10 Mengxuan S, Fen Z, Runming J. Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era. Front Pediatr 2022;10:923419. [DOI: 10.3389/fped.2022.923419] [Reference Citation Analysis]
11 Song Z, Ma L, Bao L, Ma Y, Yang P, Jiang D, Liu A, Zhang L, Li Y, Cheng Y, Dong F, Zhao R, Jing H. Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship. Front Pharmacol 2022;13:931495. [DOI: 10.3389/fphar.2022.931495] [Reference Citation Analysis]
12 Minot-This MS, Boudou-Rouquette P, Jouinot A, de Percin S, Balakirouchenane D, Khoudour N, Tlemsani C, Chauvin J, Thomas-Schoemann A, Goldwasser F, Blanchet B, Alexandre J. Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients. Pharmaceutics 2022;14:1224. [PMID: 35745797 DOI: 10.3390/pharmaceutics14061224] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Turković L, Bočkor L, Ekpenyong O, Silovski T, Lovrić M, Crnković S, Nigović B, Sertić M. Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment. Pharmaceuticals 2022;15:614. [DOI: 10.3390/ph15050614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Verougstraete N, Stove V, Verstraete AG, Stove CP. Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples. Front Oncol 2022;12:821807. [PMID: 35392223 DOI: 10.3389/fonc.2022.821807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Abruzzese E, Aureli S, Bondanini F, Ciccarone M, Cortis E, Di Paolo A, Fabiani C, Galimberti S, Malagola M, Malato A, Martino B, Trawinska MM, Russo D, de Fabritiis P. Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer. J Clin Med 2022;11:1801. [PMID: 35407407 DOI: 10.3390/jcm11071801] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Bouchet S, Molimard M. Pharmacokinetics and therapeutic drug monitoring of anticancer protein/kinase inhibitors. Therapie 2022;77:157-70. [PMID: 35101282 DOI: 10.1016/j.therap.2021.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Barnett S, Holden V, Campbell-Hewson Q, Veal GJ. Perspectives and Expertise in Establishing a Therapeutic Drug Monitoring Programme for Challenging Childhood Cancer Patient Populations. Front Oncol 2021;11:815040. [PMID: 35071019 DOI: 10.3389/fonc.2021.815040] [Reference Citation Analysis]
18 Jeelan Basha N, Basavarajaiah SM, Shyamsunder K. Therapeutic potential of pyrrole and pyrrolidine analogs: an update. Mol Divers. [DOI: 10.1007/s11030-022-10387-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Schmulenson E, Zimmermann N, Mikus G, Joerger M, Jaehde U. Current status and future outlooks on therapeutic drug monitoring of fluorouracil. Expert Opin Drug Metab Toxicol 2022. [PMID: 35029518 DOI: 10.1080/17425255.2021.2029403] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Cheng LZ, Huang DL, Liao M, Li KM, Wu ZQ, Cheng YX. Structural Optimization and Improving Antitumor Potential of Moreollic Acid from Gamboge. Molecules 2022;27:482. [PMID: 35056797 DOI: 10.3390/molecules27020482] [Reference Citation Analysis]
21 Verougstraete N, Stove CP. Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors. J Pharm Biomed Anal 2022;207:114418. [PMID: 34655987 DOI: 10.1016/j.jpba.2021.114418] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
22 Brüggemann RJ, Verheggen R, Boerrigter E, Stanzani M, Verweij PE, Blijlevens NMA, Lewis RE. Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. The Lancet Haematology 2022;9:e58-72. [DOI: 10.1016/s2352-3026(21)00232-5] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
23 Wills KH, Behan SJ, Nance MJ, Dawson JL, Polasek TM, Hopkins AM, van Dyk M, Rowland A. Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine Exposure. Pharmaceutics 2021;14:47. [PMID: 35056943 DOI: 10.3390/pharmaceutics14010047] [Reference Citation Analysis]
24 Kehl N, Schlichtig K, Dürr P, Bellut L, Dörje F, Fietkau R, Pavel M, Mackensen A, Wullich B, Maas R, Fromm MF, Gessner A, Taudte RV. An Easily Expandable Multi-Drug LC-MS Assay for the Simultaneous Quantification of 57 Oral Antitumor Drugs in Human Plasma. Cancers (Basel) 2021;13:6329. [PMID: 34944950 DOI: 10.3390/cancers13246329] [Reference Citation Analysis]
25 Mc Laughlin AM, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland SL, Huitema ADR, Steeghs N, Müller L, Fuxius S, Illerhaus G, Joerger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium. Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers (Basel) 2021;13:6281. [PMID: 34944899 DOI: 10.3390/cancers13246281] [Reference Citation Analysis]
26 Boosman RJ, Burgers JA, Smit EF, Steeghs N, van der Wekken AJ, Beijnen JH, Huitema ADR, Ter Heine R. Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. Drugs 2021. [PMID: 34894338 DOI: 10.1007/s40265-021-01654-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Zhang M, Liu X, Chen Z, Jiang S, Wang L, Tao M, Miao L. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC–MS/MS for therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis 2021. [DOI: 10.1016/j.jpba.2021.114562] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Braal CL, Jager A, Hoop EO, Westenberg JD, Lommen KMWT, de Bruijn P, Vastbinder MB, van Rossum-Schornagel QC, Thijs-Visser MF, van Alphen RJ, Struik LEM, Zuetenhorst HJM, Mathijssen RHJ, Koolen SLW. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clin Pharmacokinet 2021. [PMID: 34786650 DOI: 10.1007/s40262-021-01077-z] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
29 Ito T, Yamamoto K, Furukawa J, Harada K, Fujisawa M, Omura T, Yano I. Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule. J Clin Pharm Ther 2021. [PMID: 34669974 DOI: 10.1111/jcpt.13517] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Marouille AL, Petit E, Kaderbhaï C, Desmoulins I, Hennequin A, Mayeur D, Fumet JD, Ladoire S, Tharin Z, Ayati S, Ilie S, Royer B, Schmitt A. Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients. Pharmaceutics 2021;13:1708. [PMID: 34684001 DOI: 10.3390/pharmaceutics13101708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Orlandi P, Solini A, Banchi M, Brunetto MR, Cioni D, Ghiadoni L, Bocci G. Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. Pharmaceuticals (Basel) 2021;14:995. [PMID: 34681219 DOI: 10.3390/ph14100995] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
32 Erku D, Schneider J, Scuffham P. A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology. Pharmacol Res Perspect 2021;9:e00862. [PMID: 34546005 DOI: 10.1002/prp2.862] [Reference Citation Analysis]
33 Meng Q, Wang Y, Long Y, Yue A, Mecklenburg M, Tian S, Fu Y, Yao X, Liu J, Song D, Wu C, Xie B. Rapid Detection of Multiple Classes of β-Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay. Antibiotics (Basel) 2021;10:1110. [PMID: 34572692 DOI: 10.3390/antibiotics10091110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 van Dyk M, Bulamu N, Boylan C, Mc Laughlin AM, Kichenadasse G, May N, Michelet R, Kloft C, Kaambwa B. Cost-effectiveness of oral anticancer drugs and associated individualised dosing approaches in patients with cancer: protocol for a systematic review. BMJ Open 2021;11:e047173. [PMID: 34404700 DOI: 10.1136/bmjopen-2020-047173] [Reference Citation Analysis]
35 Dai L, Lv P, He Y, Wang X, Chen L, Dai J. A Novel LC-MS Method for the Determination of Abiraterone in Rat Plasma and its Application to Pharmacokinetic Studies. CPA 2021;18. [DOI: 10.2174/2213337208666210816112837] [Reference Citation Analysis]
36 Villanueva-Bueno C, Escudero-Vilaplana V, Collado-Borrell R, Giménez-Manzorro Á, Ribed A, Marzal-Alfaro B, Revuelta-Herrero JL, Gonzalez-Haba E, Herranz A, Sanjurjo M. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients. Expert Opin Drug Saf 2021;:1-13. [PMID: 34357828 DOI: 10.1080/14740338.2021.1965990] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Fahmy A, Hopkins AM, Sorich MJ, Rowland A. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature. Expert Opin Drug Metab Toxicol 2021;17:803-21. [PMID: 34278936 DOI: 10.1080/17425255.2021.1943357] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Skjånes K, Aesoy R, Herfindal L, Skomedal H. Bioactive peptides from microalgae: Focus on anti-cancer and immunomodulating activity. Physiol Plant 2021. [PMID: 34085279 DOI: 10.1111/ppl.13472] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
39 Ferrer F, Chauvin J, DeVictor B, Lacarelle B, Deville JL, Ciccolini J. Clinical-Based vs. Model-Based Adaptive Dosing Strategy: Retrospective Comparison in Real-World mRCC Patients Treated with Sunitinib. Pharmaceuticals (Basel) 2021;14:494. [PMID: 34073681 DOI: 10.3390/ph14060494] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Lewis RE, Andes DR. Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions. Curr Opin Infect Dis 2021;34:288-96. [PMID: 34010233 DOI: 10.1097/QCO.0000000000000740] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Ruanglertboon W, Sorich MJ, Hopkins AM, Rowland A. Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing. Pharmaceuticals (Basel) 2021;14:389. [PMID: 33919091 DOI: 10.3390/ph14050389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 van Eerden RAG, Oomen-de Hoop E, Noordam A, Mathijssen RHJ, Koolen SLW. Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors. Pharmaceuticals (Basel) 2021;14:119. [PMID: 33557114 DOI: 10.3390/ph14020119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Mueller-Schoell A, Klopp-Schulze L, Michelet R, van Dyk M, Mürdter TE, Schwab M, Joerger M, Huisinga W, Mikus G, Kloft C. Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. Pharmaceuticals (Basel) 2021;14:115. [PMID: 33546125 DOI: 10.3390/ph14020115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]